TY - STD TI - Public Health England, Health Protection Scotland, Public Health Wales, Public Health Agency. Hepatitis C in the UK: 2014 report. 2014. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/337115/HCV_in_the_UK_2014_24_July.pdf. Accessed Jan 2015. UR - https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/337115/HCV_in_the_UK_2014_24_July.pdf ID - ref1 ER - TY - STD TI - European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. 2014. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf. Accessed Sep 2014. UR - http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf ID - ref2 ER - TY - STD TI - World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014 http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed Jan 2015. UR - http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ ID - ref3 ER - TY - JOUR AU - Kanwal, F. AU - Hoang, T. AU - Kramer, J. R. AU - Asch, S. M. AU - Goetz, M. B. AU - Zeringue, A. PY - 2010 DA - 2010// TI - Increasing prevalence of HCC and Cirrhosis in patients with chronic hepatitis C virus infection JO - Gastroenterology VL - 140 UR - https://doi.org/10.1053/j.gastro.2010.12.032 DO - 10.1053/j.gastro.2010.12.032 ID - Kanwal2010 ER - TY - JOUR AU - Oliveria Andrade, L. J. AU - D’Oliveira, A. AU - Melo, R. C. AU - Souza, E. C. AU - Costa Silva, C. A. AU - Paraná, R. PY - 2009 DA - 2009// TI - Association between hepatitis C and hepatocellular carcinoma JO - J Glob Infect Dis VL - 1 UR - https://doi.org/10.4103/0974-777X.52979 DO - 10.4103/0974-777X.52979 ID - Oliveria Andrade2009 ER - TY - JOUR AU - Bochud, P. Y. AU - Cai, T. AU - Overbeck, K. AU - Bochud, M. AU - Dufour, J. F. AU - Mullhaupt, B. PY - 2009 DA - 2009// TI - Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C JO - J Hepatol VL - 51 UR - https://doi.org/10.1016/j.jhep.2009.05.016 DO - 10.1016/j.jhep.2009.05.016 ID - Bochud2009 ER - TY - JOUR AU - Probst, A. AU - Dang, T. AU - Bochud, M. AU - Egger, M. AU - Negro, F. AU - Bochud, P. Y. PY - 2011 DA - 2011// TI - Role of hepatitis C virus genotype 3 in liver fibrosis progression—a systematic review and meta-analysis JO - J Viral Hepat VL - 18 UR - https://doi.org/10.1111/j.1365-2893.2011.01481.x DO - 10.1111/j.1365-2893.2011.01481.x ID - Probst2011 ER - TY - JOUR AU - McMahon, B. J. AU - Bruden, D. AU - Bruce, M. G. AU - Livingston, S. AU - Christensen, C. AU - Homan, C. PY - 2010 DA - 2010// TI - Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection JO - Gastroenterology VL - 138 UR - https://doi.org/10.1053/j.gastro.2009.10.056 DO - 10.1053/j.gastro.2009.10.056 ID - McMahon2010 ER - TY - JOUR AU - Larsen, C. AU - Bousquet, V. AU - Delarocque-Astagneau, E. AU - Pioche, C. AU - Roudot-Thoraval, F. AU - Desenclos, J. C. PY - 2010 DA - 2010// TI - Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France JO - J Med Virol VL - 82 UR - https://doi.org/10.1002/jmv.21850 DO - 10.1002/jmv.21850 ID - Larsen2010 ER - TY - JOUR AU - Meer, A. J. AU - Veldt, B. J. AU - Feld, J. J. AU - Wedemeyer, H. AU - Dufour, J. F. AU - Lammert, F. PY - 2012 DA - 2012// TI - Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JO - JAMA VL - 308 UR - https://doi.org/10.1001/jama.2012.144878 DO - 10.1001/jama.2012.144878 ID - Meer2012 ER - TY - JOUR AU - Nkontchou, G. AU - Ziol, M. AU - Aout, M. AU - Lhabadie, M. AU - Baazia, Y. AU - Mahmoudi, A. PY - 2011 DA - 2011// TI - HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis JO - J Viral Hepat VL - 18 UR - https://doi.org/10.1111/j.1365-2893.2011.01441.x DO - 10.1111/j.1365-2893.2011.01441.x ID - Nkontchou2011 ER - TY - JOUR AU - Kanwal, F. AU - Kramer, J. R. AU - Ilyas, J. AU - Duan, Z. AU - El-Serag, H. B. PY - 2014 DA - 2014// TI - HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV JO - Hepatology VL - 60 UR - https://doi.org/10.1002/hep.27095 DO - 10.1002/hep.27095 ID - Kanwal2014 ER - TY - JOUR PY - 2015 DA - 2015// TI - EASL recommendations on treatment of hepatitis C 2015 JO - J Hepatol VL - 63 UR - https://doi.org/10.1016/j.jhep.2015.03.025 DO - 10.1016/j.jhep.2015.03.025 ID - ref13 ER - TY - JOUR AU - McEwan, P. AU - Kim, R. AU - Yuan, Y. PY - 2013 DA - 2013// TI - Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model JO - Appl Health Econ Health Policy VL - 11 UR - https://doi.org/10.1007/s40258-012-0002-0 DO - 10.1007/s40258-012-0002-0 ID - McEwan2013 ER - TY - JOUR AU - McEwan, P. AU - Ward, T. AU - Yuan, Y. AU - Kim, R. AU - L’Italien, G. PY - 2013 DA - 2013// TI - The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States JO - Hepatology (Baltimore, Md) VL - 58 UR - https://doi.org/10.1002/hep.26304 DO - 10.1002/hep.26304 ID - McEwan2013 ER - TY - JOUR AU - McEwan, P. AU - Ward, T. AU - Chen, C. -. J. AU - Lee, M. -. H. AU - Yang, H. -. I. AU - Kim, R. PY - 2014 DA - 2014// TI - Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection JO - Value Health Reg Issues VL - 3 UR - https://doi.org/10.1016/j.vhri.2013.08.001 DO - 10.1016/j.vhri.2013.08.001 ID - McEwan2014 ER - TY - JOUR AU - Thein, H. H. AU - Yi, Q. AU - Dore, G. J. AU - Krahn, M. D. PY - 2008 DA - 2008// TI - Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression JO - Hepatology VL - 48 UR - https://doi.org/10.1002/hep.22375 DO - 10.1002/hep.22375 ID - Thein2008 ER - TY - STD TI - Office of National Statistics. National life tables, 2010–2012: UK reference tables 2013. 2014. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-325699. Accessed 14 Oct 2014. UR - http://www.ons.gov.uk/ons/publications/re-reference-tables.html%3fedition%3dtcm%253A77-325699 ID - ref18 ER - TY - STD TI - Office of National Statistics. Mortality statistics: deaths registered in England and Wales (Series DR). 2012, 2013. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-325289. Accessed Jan 2015. UR - http://www.ons.gov.uk/ons/publications/re-reference-tables.html%3fedition%3dtcm%253A77-325289 ID - ref19 ER - TY - JOUR AU - Shepherd, J. AU - Jones, J. AU - Hartwell, D. AU - Davidson, P. AU - Price, A. AU - Waugh, N. PY - 2007 DA - 2007// TI - Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation JO - Health Technol Assess (Winchester, England) VL - 11 ID - Shepherd2007 ER - TY - JOUR AU - Martin, N. K. AU - Vickerman, P. AU - Miners, A. AU - Foster, G. R. AU - Hutchinson, S. J. AU - Goldberg, D. J. PY - 2012 DA - 2012// TI - Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations JO - Hepatology VL - 55 UR - https://doi.org/10.1002/hep.24656 DO - 10.1002/hep.24656 ID - Martin2012 ER - TY - JOUR AU - Townsend, R. AU - McEwan, P. AU - Kim, R. AU - Yuan, Y. PY - 2011 DA - 2011// TI - Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C JO - Value Health VL - 14 UR - https://doi.org/10.1016/j.jval.2011.06.006 DO - 10.1016/j.jval.2011.06.006 ID - Townsend2011 ER - TY - BOOK PY - 2011 DA - 2011// TI - Telaprevir for the treatment of genotype 1 chronic hepatitis C PB - Janssen Ltd CY - High Wycombe ID - ref23 ER - TY - STD TI - Personal Social Services Research Unit. Unit costs of health and social care 2013. Section 16.2: The hospital & community health services (HCHS) index; 2013. ID - ref24 ER - TY - STD TI - National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. http://www.nice.org.uk/article/pmg9. Accessed 24 Nov 2015. UR - http://www.nice.org.uk/article/pmg9 ID - ref25 ER - TY - STD TI - Public Health England. Commissioning template for estimating HCV prevalence by DAT and numbers eligible for treatment. 2014. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HepatitisC/EpidemiologicalData/. Accessed Jul 2014. UR - http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HepatitisC/EpidemiologicalData/ ID - ref26 ER - TY - STD TI - Public Health England, Health Protection Scotland, Public Health Wales, Public Health Agency. Hepatitis C in the UK: 2013 report. 2013. http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/HepatitisCInTheUK/1307HepatitisCintheUK2013report/. Accessed Jun 2014. UR - http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/HepatitisCInTheUK/1307HepatitisCintheUK2013report/ ID - ref27 ER - TY - BOOK PY - 2014 DA - 2014// TI - Host and viral factors associated with outcomes of infection with hepatitis C virus (HCV Research UK) PB - Nottingham University Hospitals NHS Trust CY - Nottingham ID - ref28 ER - TY - JOUR AU - Nelson, D. R. AU - Cooper, J. N. AU - Lalezari, J. P. AU - Lawitz, E. AU - Pockros, P. J. AU - Gitlin, N. PY - 2015 DA - 2015// TI - All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27726 DO - 10.1002/hep.27726 ID - Nelson2015 ER - TY - JOUR AU - Zeuzem, S. AU - Dusheiko, G. M. AU - Salupere, R. AU - Mangia, A. AU - Flisiak, R. AU - Hyland, R. H. PY - 2014 DA - 2014// TI - Sofosbuvir and ribavirin in HCV genotypes 2 and 3 JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1316145 DO - 10.1056/NEJMoa1316145 ID - Zeuzem2014 ER - TY - BOOK AU - Swallow, E. PY - 2015 DA - 2015// TI - Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis C genotype 3: a matching-adjusted indirect comparison PB - The International Liver Congress CY - Vienna ID - Swallow2015 ER - TY - STD TI - National Institute for Health and Care Excellence. Judging whether public health interventions offer value for money. Local government briefing [LGB10]. 2013. https://www.nice.org.uk/advice/lgb10/chapter/judging-the-cost-effectiveness-of-public-health-activities. Accessed 13 Mar 2017. UR - https://www.nice.org.uk/advice/lgb10/chapter/judging-the-cost-effectiveness-of-public-health-activities ID - ref32 ER - TY - STD TI - Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ. 2016. pp. 1–8. doi:10.1007/s10198-016-0865-3. ID - ref33 ER - TY - JOUR AU - Crespo, J. AU - Cabezas, J. AU - Sacristán, B. AU - Olcoz, J. L. AU - Pérez, R. AU - Vega, J. PY - 2015 DA - 2015// TI - Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice JO - Liver Int VL - 35 UR - https://doi.org/10.1111/liv.12536 DO - 10.1111/liv.12536 ID - Crespo2015 ER - TY - JOUR AU - Kramer, J. R. AU - Kanwal, F. AU - Richardson, P. AU - Mei, M. AU - El-Serag, H. B. PY - 2011 DA - 2011// TI - Gaps in the achievement of effectiveness of HCV treatment in national VA practice JO - J Hepatol VL - 56 UR - https://doi.org/10.1016/j.jhep.2011.05.032 DO - 10.1016/j.jhep.2011.05.032 ID - Kramer2011 ER - TY - JOUR AU - Lee, Y. A. AU - Friedman, S. L. PY - 2014 DA - 2014// TI - Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? JO - Antivir Res VL - 107 UR - https://doi.org/10.1016/j.antiviral.2014.03.012 DO - 10.1016/j.antiviral.2014.03.012 ID - Lee2014 ER - TY - JOUR AU - Poynard, T. AU - Moussalli, J. AU - Munteanu, M. AU - Thabut, D. AU - Lebray, P. AU - Rudler, M. PY - 2013 DA - 2013// TI - Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C JO - J Hepatol VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.05.015 DO - 10.1016/j.jhep.2013.05.015 ID - Poynard2013 ER - TY - JOUR AU - Martin, N. K. AU - Vickerman, P. AU - Grebely, J. AU - Hellard, M. AU - Hutchinson, S. J. AU - Lima, V. D. PY - 2013 DA - 2013// TI - Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals JO - Hepatology VL - 58 UR - https://doi.org/10.1002/hep.26431 DO - 10.1002/hep.26431 ID - Martin2013 ER - TY - STD TI - Gilead Sciences International Ltd. Summary of product characteristics. Harvoni 90 mg/400 mg film-coated tablets. 2015. https://www.medicines.org.uk/emc/medicine/29471. Accessed Mar 2015. UR - https://www.medicines.org.uk/emc/medicine/29471 ID - ref39 ER -